地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:18771997407
邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://anogen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

成立27年来,PBL Assay Science一直协助工业界、学术界、政府研究人员开发检测方法和解决蛋白定量问题。PBL Assay Science的产品包括高品质、高灵敏度的ELISA试剂盒、干扰素蛋白和抗体等,此外PBL Assay Science还提供超灵敏细胞因子检测服务等。
Now entering our 27th year, PBL Assay Science works hand in hand with industry, academic, and government researchers to help solve difficult assay development and protein quantification problems. Known as a trusted source for high quality, high sensitivity ELISAs as well as interferon proteins and antibodies, PBL has expanded our assay services capabilities, including ultrasensitive cytokine detection services, and increased our human cell-expressed cytokine and growth factor offerings.
PBL Assay Science的主要产品包括:
(1)Assay Kits(ELISAs;Multiplex Assays;Cell-Based Assays)
(2)Proteins(Interferons,Cytokines and Growth Factors,Interferon Decoy Receptor)
(3)Antibodies(Monoclonal Antibodies (MAbs);Polyclonal Antibodies (PAbs))
(4)Assay Services(Quantitative Immunoassays;Cell-Based Services;Reagent Development)
| Assay Kits产品列表 |
| 品名 | 货号 | 规格 |
| iLite Human Type I IFN Responsive Cells | 51100 | 2.5 ml/vial |
| Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 41110-1 | 1 x 96-well plate |
| Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 41110-2 | 5 x 96-well plates |
| Human IFN-Alpha Multi-Subtype ELISA Kit (TCM) | 41105-1 | 1 x 96-well plate |
| Human IFN-Alpha Multi-Subtype ELISA Kit (TCM) | 41105-2 | 5 x 96-well plates |
| Human IFN-Alpha ELISA Kit (TCM) | 41100-1 | 1 x 96-well plate |
| Human IFN-Alpha ELISA Kit (TCM) | 41100-2 | 5 x 96-well plates |
| Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 41115-1 | 1 x 96-well plate |
| Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (TCM) | 41135-1 | 1 x 96-well plate |
| Human IFN-Beta ELISA Kit | 41410-1 | 1 x 96-well plate |
| Human IFN-Beta ELISA Kit | 41410-2 | 5 x 96-well plates |
| Human IFN-Beta TCM ELISA, High Sensitivity | 41435-1 | 1 x 96-well plate |
| Human IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 41415-1 | 1 x 96-well plate |
| Human IFNGR1 ELISA Kit (Serum, Plasma, Cell Lysate, TCM) | 41580 | 1 x 96-well plate |
| DIY Human IFN-Lambda 1/2/3 (IL-29/28A/28B) ELISA (TCM) | 61840-1 | Materials for 15 x 96-wells |
| DIY Human IFN-Lambda 2/3 (IL-28A/B) ELISA (TCM) | 61830-1 | Materials for 15 x 96-wells |
| Mouse IFN-Alpha All Subtype ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 42115-1 | 1 x 96-well plate |
| Mouse IFN-Alpha ELISA Kit (TCM) | 42120-1 | 1 x 96-well plate |
| Mouse IFN-Alpha ELISA Kit (TCM) | 42120-2 | 5 x 96-well plates |
| Mouse IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 42410-1 | 1 x 96-well plate |
| Mouse IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 42410-2 | 5 x 96-well plates |
| Mouse IFN-Beta ELISA Kit (TCM, Serum) | 42400-1 | 1 x 96-well plate |
| Mouse IFN-Beta ELISA Kit (TCM, Serum) | 42400-2 | 5 x 96-well plates |
| DIY Mouse IFN-Lambda 2/3 (IL-28A/B) ELISA (TCM) | 62830-1 | Materials for 15 x 96-wells |
| Pig IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 47100-1 | 1 x 96-well plate |
| Cynomolgus IFN-Beta ELISA Kit (Serum, Plasma, TCM) | 46415-1 | 1 x 96-well plate |
| Cynomolgus/Rhesus IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 46100-1 | 1 x 96-well plate |
| Human IL-22 ELISA, High Sensitivity (Serum, Plasma, TCM) | 41701-1 | 1 x 96-well plate |
| Total Human IL-15 ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 41702-1 | 1 x 96-well plate |
| Proteins产品列表 |
| 品名 | 货号 | 规格 |
| Human IFN-Lambda 2, Human Cell Expressed | 11720-1 | ≥ 1 x 10⁵ units |
| Human IFN-Lambda 3, Human Cell Expressed | 11730-1 | ≥ 1 x 10⁵ units |
| Human IFN-Lambda 1, Human Cell Expressed | 11725-1 | ≥ 1 x 10⁵ units |
| Human Erythropoietin (EPO), Ultrapure | 11965-1 | 500 units |
| Human Interleukin 22 (Human Cell-Expressed) | 11701-1 | 10 μg |
| Human Interleukin 22 (Human Cell-Expressed) | 11701-2 | 50 μg |
| Human Interleukin 15 / IL-15Rα Heterodimer (Human Cell-Expressed) | 11702-1 | 10 μg |
| Human Interleukin 15 / IL-15Rα Heterodimer (Human Cell-Expressed) | 11702-2 | 50 μg |
| Mouse Interferon Alpha All-Subtype Neutralizing Viral Protein | 12185-1 | 10 μg |
| Mouse Interferon Alpha All-Subtype Neutralizing Viral Protein | 12185-2 | 100 μg |
| UniversalTM Type I IFN (Human IFN-Alpha Hybrid Protein) | 11200-1 | 1 x 10⁵ units |
| UniversalTM Type I IFN (Human IFN-Alpha Hybrid Protein) | 11200-2 | 1 x 10⁶ units |
| Human IFN-Beta 1a, mammalian, carrier-free | 11410-2 | 1 x 10⁶ units |
| Human IFN-Beta (Beta 1a, Mammalian Expressed) | 11415-1 | 1 x 10⁵ units |
| Human IFN-Alpha Sampler Set | 11002-1 | 1 x 10⁵ units |
| Human IFN-Alpha 2a (Alpha A) Protein | 11100-1 | 5 x 10⁶ units |
| Human IFN-Alpha 2a (Alpha A) Protein, Carrier-Free | 11101-1 | 5 μg |
| Human IFN-Alpha 2a (Alpha A) Protein, Carrier-Free | 11101-2 | 20 μg |
| Human IFN-Alpha 2b (Alpha 2) Protein | 11105-1 | 1 x 10⁵ units |
| Human IFN-Alpha 8 (Alpha B2) Protein | 11115-1 | 1 x 10⁵ units |
| Human IFN-Alpha 10 (Alpha C) Protein | 11120-1 | 1 x 10⁵ units |
| Human IFN-Alpha 1 (Alpha D) Protein | 11125-1 | 1 x 10⁵ units |
| Human IFN-Alpha 21 (Alpha F) Protein | 11130-1 | 1 x 10⁵ units |
| Human IFN-Alpha 5 (Alpha G) Protein | 11135-1 | 1 x 10⁵ units |
| Human IFN-Alpha 14 (Alpha H2) Protein | 11145-1 | 1 x 10⁵ units |
| Human IFN-Alpha 17 (Alpha I) Protein | 11150-1 | 1 x 10⁵ units |
| Human IFN-Alpha 7 (Alpha J1) | 11160-1 | 1 x 10⁵ units |
| Human IFN-Alpha 6 (Alpha K) Protein | 11165-1 | 1 x 10⁵ units |
| Human IFN-Alpha D (Alpha 1) Protein | 11175-1 | 1 x 10⁵ units |
| Human IFN-Alpha 4a (Alpha M1) Protein | 11177-1 | 1 x 10⁵ units |
| Human IFN-Alpha 4b (Alpha 4) Protein | 11180-1 | 1 x 10⁵ units |
| Human IFN-Alpha 16 (Alpha WA) Protein | 11190-1 | 1 x 10⁵ units |
| Human IFN-Omega | 11395-1 | 25 μg |
| Human IFN-Beta 1b, E.Coli | 11420-1 | 1 x 10⁵ units |
| Human IL-28A/IFN-Lambda 2, Carrier-Free | 11821-1 | 25 μg |
| Human IL-29/IFN-Lambda 1, Carrier-Free | 11826-1 | 25 μg |
| Human IFN-Gamma | 11500-1 | 50 μg |
| Human IFN-Gamma | 11500-2 | 100 μg |
| Cynomolgus IFN-Alpha 2 (Ile 16), Mammalian | 16105-1 | 1 x 10⁵ units |
| Rhesus/Cynomolgus IFN-Alpha 2 | 14110-1 | 1 x 10⁵ units |
| Feline IFN-Alpha | 15100-1 | 1 x 10⁵ units |
| Porcine IFN-Alpha | 17105-1 | 1 x 10⁵ units |
| Bovine IFN-Tau 2, Mammalian | 19616-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, Mammalian | 12405-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, Mammalian, Carrier-Free | 12410-1 | 1 x 10⁶ units |
| Mouse IFN-Alpha A | 12100-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 1 | 12105-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 4, mammalian | 12115-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 11 | 12125-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 13 | 12130-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, E.Coli | 12400-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, Carrier-Free | 12401-1 | 1 x 10⁵ units |
| Mouse IL-28B/IFN-Lambda 3 | 12820-1 | 25 μg |
| Mouse IL-28B/IFN-Lambda 3, Carrier-Free | 12821-1 | 25 μg |
| Rat IFN-Alpha 1, Mammalian | 13101-1 | 10 μg |
| Rat IFN-Alpha 14, Mammalian | 13114-1 | 10 μg |
| Rat IFN-Alpha 1 | 13100-1 | 1 x 10⁵ units |
| Rat IFN-Beta | 13400-1 | 1 x 10⁵ units |
| Rat IFN-Gamma | 13500-1 | 10 μg |
| Antibodies产品列表 |
| 品名 | 货号 | 规格 |
| Anti-Human IFN-Alpha, Clone MMHA-2 (MAb) | 21100-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-2 (MAb) | 21100-2 | 500 μg |
| Anti-Human IFN-Alpha, Clone MMHA-1 (MAb) | 21105-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-11 (MAb) | 21112-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-13(MAb) | 21116-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-17 (MAb) | 21118-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-6 (MAb) | 21125-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-9 (MAb) | 21127-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-14 (MAb) | 21129-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-8 (MAb) | 21110-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-3 (MAb) | 21400-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-1 (MAb) | 21405-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-2 (MAb) | 21410-1 | 500 μg |
| Anti-Human IFN-Beta, Clone MMHB-12 (MAb) | 21450-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-13 (MAb) | 21455-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-14 (MAb) | 21460-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-15 (MAb) | 21465-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-16 (MAb) | 21470-1 | 50 μg |
| Anti-Human IFN-Alpha/Beta Receptor 1 Antibody, Clone MMHAR-3 | 21370-1 | 50 μg |
| Anti-Human IFN-Alpha/Beta Receptor Chain 2, Clone MMHAR-2 (MAb) | 21385-1 | 50 μg |
| Anti-Human IFN-Gamma Receptor Chain 2, Clone MMHGR-2 (MAb) | 21585-1 | 250 μg |
| Anti-Human IFN-Lambda Receptor 1, Clone MMHLR-1 (MAb) | 21885-1 | 50 μg |
| Anti-Human IFN-Lambda Receptor 1, Clone HLR14 (MAb) | 21886-1 | 50 μg |
| Anti-Human IFN-Gamma, Clone MMHG-1 (MAb) | 21500-1 | 500 μg |
| Anti-Human IFN-Gamma, Clone MMHG-2 (MAb) | 21550-1 | 100 μg |
| Anti-Human IFN-Gamma Receptor Chain 2, Clone MMHGR-2 (MAb) | 21585-1 | 250 μg |
| Anti-Human IL-28A/IFNL2, neutralizing, Clone MMHL-2 (MAb) | 21720-1 | 200 μg |
| Anti-Human Interleukin-28B/Interferon Lambda 3, neutralizing, Clone MMHL-3 (MAb) | 21730-1 | 100 μg |
| Anti-Human ISG15, Clone 2.1 (MAb) | 21900-1 | 100 μg |
| Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 22100-1 | 250 μg |
| FITC Conjugated Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 22100-3 | 25 μg |
| Anti-Mouse IFN-Beta, Clone RMMB-1 (MAb) | 22400-1 | 250 μg |
| Anti-Mouse IFN-Gamma, Clone RMMG-1 (MAb) | 22500-1 | 500 μg |
| Anti-Pig IFN-Alpha, Clone K9 (MAb) | 27100-1 | 500 μg |
| Anti-Pig IFN-Alpha, Clone F17 (MAb) | 27105-1 | 500 μg |
| FITC Conjugated Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 22100-3 | 25 μg |
| Anti-Human IFN-Alpha, Rabbit Serum (PAb) | 31101-1 | 1 x 10⁵ units |
| Anti-Human IFN-Alpha, Sheep Serum (PAb) | 31110-1 | 1 x 10⁵ units |
| Anti-Human IFN-Alpha (All Subtypes), Rabbit Serum (PAb) | 31135-1 | 1 x 10⁵ units |
| Anti-Human IFN-Beta, Sheep Serum (PAb) | 31401-1 | 2 x 10⁴ units |
| Anti-Human IFN-Beta, Rabbit IgG, protein A purified (PAb) | 31405-1 | 2 x 10⁴ units |
| Anti-Human IFN-Beta, Rabbit Serum (PAb) | 31410-1 | 2 x 10⁴ units |
| Anti-Human IFN-Beta, Goat IgG, Affinity Purified (PAb) | 31420-1 | 100 μg |
| Anti-Human IFN-Gamma, Rabbit Serum (PAb) | 31500-1 | 2 x 10⁴ units |
| Human Type I IFN Neutralizing Antibody Mixture | 39000-1 | 0.2 ml |
| Anti-Mouse IFN-Alpha, Rabbit Serum (PAb) | 32100-1 | 2 x 10⁴ units |
| Anti-Mouse IFN-Alpha, Chicken IgY, Purified (PAb) | 32120-1 | 500 μg |
| Anti-Mouse IFN-Beta, Rabbit Serum (PAb) | 32400-1 | 2 x 10⁴ units |
| Anti-Mouse IFN-Beta, Rabbit IgG, Protein A purified (PAb) | 32401-1 | 2 x 10⁴ units |
| Anti-Mouse IFN-Gamma, Rabbit Serum (PAb) | 32500-1 | 2 x 10⁴ units |
| Anti-Rat IFN-Alpha, Rabbit IgG, Protein A Purified (PAb) | 33100-1 | 500 μg |
| Anti-Rat IFN-Beta, Rabbit IgG, Protein A purified (PAb) | 33400-1 | 500 μg |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Dianova公司为德国著名的病理免疫组化产品供应商,具备领先的抗体制备工艺及严格的质控系统,产品在国际上享有良好的声誉。
Since its foundation in 1982, dianova GmbH provides professionals in Life Sciences with antibodies, immunoassays, and products for molecular biology. More than 30 years of grown expertise give rise to a fundamental knowledge about biochemical applications and a profound understanding of customer needs in research and routine diagnostic laboratories of universities, hospitals and the pharmaceutical industry.
Dianova公司的主要产品包括:
Proteine
Assays / Kits
Reagenzien / Medien
Material
Geräte
Antikörper-Service
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://anogen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Dianova"> Dianova
美国Plant Cell Technology公司为商业及研究用植物组织培养实验室和植物种植者开发、生产了旗舰产品PPM™ (Plant Preservative Mixture),它是一种广谱抗微生物剂,可以杀死细菌和真菌细胞,防止真菌孢子的萌发,并在较高浓度下能消除内源性污染的外植体。研究表明PPM™活性成分可以渗透过真菌或细菌细胞壁,抑制柠檬酸循环和电子传递链等中心代谢循环中的关键酶的活性,并且可以抑制培养基中的单糖和氨基酸向真菌和细菌细胞的运输。PPM™能有效地抑制植物细胞和植物组织培养中的通过空气、水、人传播的微生物污染及内源性污染,而不会影响体外种子发芽、愈伤组织增殖和愈伤组织的再生。并且,PPM™具有热稳定性,可以和培养基一起灭菌,同时比常用抗生素价更低廉,可以作为植物组织培养基的标准成分。
The principal PCT scientist involved in the development of the PPM™ application is Dr. Assaf Guri. Dr. Assaf Guri holds degrees in genetics, applied genetics and plant breeding from the Hebrew University in Jerusalem and Michigan State University in the US. Before joining Plant Cell Technology, Inc., Dr. Guri worked with the Volcani Agricultural Research Center in Israel, Michigan State University in East Lansing, Michigan and DNAP in New Jersey.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
<艾美捷科技代理Cypex品牌全系列产品
BioIVT作为生命科学和诊断行业的领军企业,专注于提供健康对照与疾病状态样本,包括人和动物的组织或制品、ADME-Tox产品及研究服务、细胞与基因治疗产品、血液及其他生物流体。凭借其在控制和疾病状态样本领域的专注与深耕,BioIVT助力全球科研工作者实现更智能的科学研究,加速医学突破的步伐。

▍Cypex产品线
● 生物体液(血液来源):提供用于生物标志物发现和临床前研究的人和动物全血、血浆、血清及其他血液来源的生物样本。涵盖骨髓、巴菲大衣、脐带血、白磷、经血、血浆和血清、血小板、红细胞、全血等多种样本类型,满足不同研究方向的需求。
● 生物体液(其他):拥有即装即用的库存,包含各种正常的人类和动物生物体液,如胃肠道生物体液、脂肪抽吸液、眼部生物体液、生殖生物体液、呼吸生物液、唾液、Transcellular Fluid、尿等,提供便捷的研究资源。
● 细胞产品:涵盖脂肪细胞、BMMC、细胞提取物、条件介质、解离的肿瘤细胞、内皮细胞、Epithelial Cells、成纤维细胞、HEPATOMUNE培养物、HEPATOPAC培养物、肝细胞、永生化癌细胞系等众多类型,还包含角质形成细胞、黑色素细胞、Musculoskeletal Cells、非实质细胞、眼细胞、PBMC、周细胞、前细胞、纯化免疫细胞亚群、肾细胞、呼吸细胞、皮肤细胞、干细胞、组织来源的免疫细胞、运输产品等,满足不同研究方向需求。
● 外泌体:来源多样:包括血液外泌体(人)、Mesenchymal Stem Cells(人)、人脐带血血清外泌体、人胎盘来源的外泌体、人前细胞外泌体等。提供外泌体批次的广泛表征分析,包括大小和数量测定、表面蛋白表达、miRNA表达与测序、用于蛋白质组学和脂质组学的LS/MS、电子显微镜观察、稳定性测试、特定目标蛋白质的蛋白质印迹以及多种功能测定。
● 培养基/试剂/试剂盒:养提供培养基、血清和即用型试剂盒,满足细胞培养需求。提供ADME培养基/试剂,用于孵育、解冻和接种肝细胞培养,确保实验最佳条件。提供化学药品,包含高质量化学品,如对照细胞色素P450(CYP)底物及其相应的代谢物,用于早期药物发现服务,帮助加快候选药物选择。
● 分子产物:总RNA、总核酸 - 糖尿病、总RNA - 代谢等产品,为基因表达分析、疾病机制研究等提供了高质量的原料。这些核酸产物经过严格的质量控制,确保其纯度和完整性,满足各种分子生物学实验的需求。
● 亚细胞组分和重组酶:包括匀浆、微粒体、S9、胞浆、非CYP重组酶、细胞等。这些亚细胞组分经过精细的分离和纯化工艺,保留了其原有的生物活性和功能。
● 组织:人体组织及动物组织
①人体组织:其ASTERAND®人体组织标本涵盖了皮肤、软组织、、泌尿系统、中枢神经系统、内分泌腺、胃肠、头颈部、肝、淋巴、乳房、肌肉骨骼、生殖、呼吸等多个系统和器官的组织。这些组织标本经过严格的收集和处理流程,确保其质量和可靠性。
②动物组织:提供来自任何市售动物研究模型的动物组织,如大脑、肾脏、肺、肠道、心脏和皮肤等组织类型的定制制剂,为动物模型研究提供了丰富的资源。
▍Cypex部分产品列表
| 品名 | 货号 | 描述 |
| Human Bone Marrow Aspirate | BOV00BMAK2MP | Bovine Bone Marrow Aspirate K2EDTA Pooled Male |
| Human Bone Marrow Aspirate | HUMANBMANH-0043290 | Human Bone Marrow Aspirate NaHep Normal Frozen, 1mL |
| Human Bone Marrow Aspirate | CUSTOMCELL | Human Bone Marrow Aspirate |
| Non-Human Primate Bone Marrow Aspirate | NHP01BMAK2-0115680 | Cynomolgus Monkey Bone Marrow Aspirate K2EDTA Gender Pooled |
| Non-Human Primate Bone Marrow Aspirate | NHP01BMAK2-0105114 | Cynomolgus Monkey Bone Marrow Aspirate K2EDTA Gender Unspecified |
| Non-Human Primate Bone Marrow Aspirate | NHP01BMAK2-0105116 | Cynomolgus Monkey Bone Marrow Aspirate K2EDTA Gender Unspecified Pooled |
| Non-Human Primate Bone Marrow Aspirate | NHP01BMAK2-0116317 | Cynomolgus Monkey Bone Marrow Aspirate K2EDTA Male |
| Non-Human Primate Bone Marrow Aspirate | NHP01BMAK2-0109008 | Cynomolgus Monkey Bone Marrow Aspirate K2EDTA Male Pooled |
| Non-Human Primate Bone Marrow Aspirate | NHP02BMAK2-0121295 | Rhesus Monkey Bone Marrow Aspirate K2EDTA Gender Unspecified Pooled |
| Non-Human Primate Bone Marrow Aspirate | NHP02BMAK2-0126229 | Rhesus Monkey Bone Marrow Aspirate K2EDTA Male |
| Non-Human Primate Bone Marrow Aspirate | CUSTOMBIOF | Non-Human Primate Bone Marrow Aspirate |
| Mouse Bone Marrow Aspirate | MSE02BMANHP | BALB/C Mouse Bone Marrow Aspirate NaHep Gender Pooled |
| Mouse Bone Marrow Aspirate | MSE01BMANHP | C57BL/6 Mouse Bone Marrow Aspirate NaHep Gender Pooled |
| Mouse Bone Marrow Aspirate | MSE00BMANHP | CD-1 (ICR) Mouse Bone Marrow Aspirate NaHep Gender Pooled |
| Mouse Bone Marrow Aspirate | CUSTOMCELL | Mouse Bone Marrow Aspirate |
| Human Heme-Oncology Bone Marrow | CUSTOMBIOFBLDDS | Human Heme-Oncology Bone Marrow |
| Normal Human Buffy Coat | CUSTOMCELL | Normal Human Buffy Coat |
| Human Cord Blood | HUMANCBCPD-0119137 | Human Cord Blood CPD Female Not Viral Tested Fresh |
| Human Cord Blood | HUMANCBCPD-0119138 | Human Cord Blood CPD Female Viral Negative Fresh |
| Human Cord Blood | HUMANCBPCPD-0129988 | Human Cord Blood Plasma CPD Gender Unspecified, 10mL Frozen |
| Human Cord Blood | HUMANCBS-0129990 | Human Cord Blood Serum Gender Unspecified |
| Human Cord Blood | HUMANCBS-0129989 | Human Cord Blood Serum Gender Unspecified, 1mL Frozen |
| Normal Human GMP VivoSTART™ Leukopak | HUMANGLMX100-0117880 | Human GMP VivoSTART Full Pak Gender Unspecified Cryopreserved |
| Normal Human GMP VivoSTART™ Leukopak | HUMANGLMX100-0109051 | Human GMP VivoSTART Full Pak Gender Unspecified Fresh |
| Normal Human GMP VivoSTART™ Leukopak | HUMANGLMX50-0131914 | Human GMP VivoSTART Half Pak Gender Unspecified Cryopreserved |
| Normal Human GMP VivoSTART™ Leukopak | HUMANGLMX25-0131912 | Human GMP VivoSTART Qtr Pak Gender Unspecified Cryopreserved |
| Normal Human GMP VivoSTART™ Leukopak | HUMANGLMX15B-0131909 | Human GMP VivoSTART XL Gender Unspecified Cryopreserved |
| Normal Human GMP VivoSTART™ Leukopak | HUMANGLMX15B-0131908 | Human GMP VivoSTART XL Gender Unspecified Fresh |

艾乐美生物科技有限公司(AllerMAbs Co., Ltd.)成立于2015年,是台湾一家专注于生产高亲和力、高纯度并具有过敏原特异性的嵌合人类IgE单克隆抗体的生物公司。公司创办人团队在科研过程中发现市面上缺乏多样的IgE单克隆抗体,特別是具有过敏原特异性的人IgE 单抗。如果能制备出这种抗体,将有助于IgE 相关领域的研究工作。因此,AllerMAbs公司团队开始思考与研究利用基因克隆动物来制造人类 IgE 抗体的可行性,经过数年的努力于 2014年开发出人类IgE 抗体基因嵌入小鼠,通过杂交瘤技术 (Hybridoma technology),成功地研制出分泌嵌合人类IgE 单抗的 IgE 杂交瘤与纯化 IgE 抗体。经测试,此种嵌合人类IgE 单抗的物化性质与对免疫细胞的活性,皆与人类IgE 抗体一致,研究成果于2015 年发表在国际学术期刊上。
AllerMAbs的产品解决了目前人类IgE抗体不易制备的问题,让嵌合人类IgE抗体可以成为人类IgE抗体的替代品,并提供一个更稳定、更符合血清IgE检测系统的校正品,让临床血清IgE的检测结果更加准确与可靠。
其利用动物基因转殖技术,将组成人类IgE抗体分子的ε重链(Heavy chain)和κ轻链(Light chain)的编码基因(Encoding genes),分別嵌入(Knock-in)小鼠胚胎干细胞(Embryonic stem cells, ES cells)的γ1重链和κ轻链基因的位置,接着把胚胎干细胞分別植入孕母鼠体内,并将其带有嵌入基因之成鼠交互配种,最后得到带有人类IgE抗体重链和轻链基因的基因嵌入小鼠(HεκKI mice),且体内能制造完整的嵌合人类IgE抗体分子。
技术优势
容易制备IgE杂交瘤与IgE单抗
过敏原特异性
良好的亲和力与专一性
高纯度与高稳定性
可结合至嗜碱性粒细胞上的IgE受体与刺激細胞
可大量生产与高浓度制备
非人类血液来源(相较于血清IgE抗体)
适合用作检测用的校正品
" data-original="http://anogen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="AllerMAbs"> AllerMAbs

艾美捷科技代理Biotium品牌全系列染料产品。
Biotium一直致力于开发和生产用于生物医学研究的荧光指示剂及其他特殊生化产品。其产品被广泛应用于细胞生 物学、蛋白质组学、分子生物学、免疫学、微生物学、诊断学、生物化学、神经科学、血液流动检测及大规模药物筛选等众多领域。产品列表如下:
| 产品名称 | 货号 | 规格 | |
| GelRed® Nucleic Acid Gel Stain 10000X in water, 0.5ml | 41003 | 0.5ml | |
| GelRed® Nucleic Acid Gel Stain 10000X in water, 10ml | 41003-1 | 10ml | |
| GelRed® Nucleic Acid Gel Stain 3X in water, 4L | 41001 | 4L | |
| GelRed® Nucleic Acid Gel Stain 10000X in DMSO, 0.5ml | 41002 | 0.5ml | |
| GelRed® Nucleic Acid Gel Stain 10000X in DMSO, 10ml | 41002-1 | 10ml | |
| GelGreen® Nucleic Acid Gel Stain 10000X in water, 0.5ml | 41005 | 0.5ml | |
| GelGreen® Nucleic Acid Gel Stain 10000X in water, 10ml | 41005-1 | 10ml | |
| GelGreen® Nucleic Acid Gel Stain 10000X in DMSO, 0.5ml | 41004 | 0.5ml | |
| GelRed® Agarose LE, 5g | 41029-5G | 5g | |
| GelRed® Agarose LE, 50g | 41029-50G | 50g | |
| GelGreen® Agarose LE, 5g | 41030-5G | 5g | |
| GelGreen® Agarose LE, 50g | 41030-50G | 50g | |
| 6X GelRed® Prestain Loading Buffer with Orange Tracking Dye | 41010 | 1ml | |
| PAGE GelRed® Nucleic Acid Gel Stain 10000X in water, 0.1ml | 41008-T | 0.1ml | |
| PAGE GelRed® Nucleic Acid Gel Stain 10000X in water, 500uL | 41008-500uL | 500ul | |
| PAGE GelRed® Nucleic Acid Gel Stain 1X in water, 4L | 41014 | 4L | |
| RedDot™2 Far-Red Nuclear Stain, 200X in DMSO, 25 uL | 40061-T | 25ul | |
| RedDot™2 Far-Red Nuclear Stain, 200X in DMSO, 250 uL | 40061 | 250ul | |
| RedDot™2 Far-Red Nuclear Stain, 200X in DMSO, 1 mL | 40061-1 | 1ml | |
| EvaGreen® Dye, 20X in Water, 1mL | 31000-T | 1ml | |
| EvaGreen® Dye, 20X in Water, 5 x 1 mL | 31000 | 5x1ml | |
| AO Succinimidyl Ester | 40074 | 5mg | |
| DMAO, 2 mM in DMSO | 40012 | 1ml | |
| EB Succinimidyl Ester | 40072 | 5mg | |
| Ethidium Homodimer III (EthD-III) | 40050 | 1mg | |
| Ethidium Homodimer III (EthD-III), 1 mM in DMSO | 40051 | 200ul | |
| EvaGreen® Dye, 2000X in DMSO | 31019 | 50ul | |
| MB Acid | 40076 | 5mg | |
| MB Succinimidyl Ester | 40075 | 5mg | |
| Thiazole Green (SYBR® Green I), 10,000X in DMSO, 0.5 mL | 40086-0.5mL | 0.5ml | |
| Thiazole Green (SYBR® Green I), 10,000X in DMSO, 1mL | 40086-1mL | 1ml | |
| Thiazole Orange Homodimer (TOTO®-1), 1 mM in DMSO | 40079 | 200ul | |
| Thiazole Orange, 10 mM in DMSO | 40077 | 1mL | |
| Thiazole Red (TO-PRO®-3), 1 mM in DMSO | 40087 | 1mL | |
| Thiazole Red Homodimer (TOTO®-3), 1 mM in DMSO | 40080 | 200ul | |
| TO Succinimidyl Ester | 40073 | 5mg | |
| DAPI, 10 mg | 40011 | 10mg | |
| DAPI, 10 mg (Dilactate) | 40009 | 10mg | |
| DAPI, 1 mL (10 mg/mL) | 40043 | 1ml | |
| Ethidium Homodimer I (EthD-I), 1 mg | 40010 | 1mg | |
| Ethidium Homodimer I (EthD-I), 0.5 mL (2 mM in DMSO) | 40014 | 0.5ml | |
| GelRed® Prestain Plus 6X DNA Loading Dye | 41011 | 1ml | |
| 7-AAD, 1mg | 40037 | 1mg | |
| 7-AAD, 1 mL (1 mg/mL) | 40084 | 1ml | |
| Acridine Orange, 10 mg/mL in Water (High Purity) (AO) | 40039 | 10ml | |
| Actinomycin D | 40038 | 10mg | |
| DiSC2(5) (High Purity) | 40041 | 50mg | |
| DODC (High Purity) | 40040 | 50mg | |
| Ethidium Bromide, 10 mg/mL in H2O | 40042 | 10ml | |
| Hoechst 33258, 10 mL (10 mg/mL) | 40044 | 10ml | |
| Hoechst 33258, 100mg | 40045 | 100mg | |
| Hoechst 33342, 10 mL (10 mg/mL) | 40046 | 10ml | |
| Hoechst 33342, 100mg | 40047 | 100mg | |
| PMAxx™ Dye, 20 mM in H2O | 40069 | 100ul | |
| Propidium Iodide (PI), 10 mL (1 mg/mL in Water) | 40017 | 10ml | |
| Propidium Iodide (PI), 2 mL (50 ug/mL in Buffer) | 40048 | 2ml | |
| Propidium Iodide (PI), 100 mg | 40016 | 100mg | |
| PMA (Propidium Monoazide), 100uL | 40019 | 100ul | |
| PMA (Propidium Monoazide), 1mg | 40013 | 1mg | |
| Ethidium Monoazide Bromide (EMA) | 40015 | 1mg |

Chem Service公司成立于1962年,专注于制造高品质、高纯度的标准物质。
Established in 1962, Chem Service is accredited to ISO Guide 34:2009, ISO/IEC 17025:2005, and registered and certified to the ISO 9001:2008 Quality Management System for the design, development, production, distribution, and servicing of organic neat and synthetic reference materials.
Chem Service, Inc. produces high purity standards for use as reference materials and for other laboratory purposes. More than 95% of our Standards Grade materials have a certified purity of 98.0% or greater and do not require purity corrections when preparing solutions for use with EPA, USTM, UST, and numerous other international methods. You can trust that our high purity standards are a quality product.
Standards Grade chemicals are clearly labeled with an expiration date that is based on years of experience in handling and testing. Products are packaged in small quantities to minimize storage, waste, and disposal requirements. Organic and inorganic chemicals, solutions, and mixtures are available to meet a wide range of specialized laboratory needs.
" data-original="http://anogen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Chem Service"> Chem Service
艾美捷科技特约代理BioPorto Diagnostics A/S公司产品。
BioPorto Diagnostics A/S公司成立于2001年,是丹麦一家专门生产抗体和基于抗体的各种生物产品的公司。BioPorto拥有Bioporto Diagnostics和Antibodyshop两个品牌,分别侧重于诊断试剂盒和抗体产品。在30多个国家有代理商,产品销售网络遍布全球,99%以上为出口销售。BioPorto Diagnostics旗下产品主要为几种临床快速诊断试剂盒,包括诊断早期急性肾损伤的NGAL ELISA kit,Gc-globulin ELISA kit ,评估原发性免疫缺陷的MBL Oligomer ELISA kit,同时还有相关其他种属的科研用试剂盒和抗原抗体。其最新推出的产品有检测人体血浆中的活性蛋白C-蛋白C抑制物(APC-PCI)复合物的APC-PCI ELISA kit,高纯度人IgE单克隆抗体,以及Glucagon-like peptide-1和Exendin-4相关的单抗。
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
< " data-original="http://anogen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Bioporto"> Bioporto
R&D Systems位于美国的明尼苏达州,一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1977年,公司推出第一个产品--富血小板血浆质控品;1981年,公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中,R&D Systems仍持续开发各种血控品产品。
1985年,作为公司推出的第一个科研试剂产品,也是全球第一家将该产品进行商业化生产的产品,R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子,TGF-beta1蛋白在多种细胞中进行表达,并作为胞外信号分子参与免疫功能,细胞增殖和细胞分化等生物学过程。该产品推出后,公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。天然蛋白类产品的成功推广,加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部(现Biotechnology事业部)。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较,DNA重组技术生产的蛋白产品其成本更低,产量更高,完全摆脱原料的限制。1989年,Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体,并于1990年开发了第一个ELISA试剂盒。
R&D System的主要产品包括:
Recombinant Proteins
GMP Proteins
Antibodies
ELISAs
Luminex Assays & High Performance Assays
Stem Cell Products
Cell Culture
Small Molecules & Peptides
Enzymes
ELISpots
cDNA Clones
Flow Cytometry Workflow Solutions
Proteome Profiler Antibody Arrays
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://anogen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="R&D System"> R&D System地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:17754422825
邮箱:sales@amyjet.com
0.3576